Enfortumab vedotin + pembrolizumab shrank locally advanced and metastatic #BladderCancer tumors in 64.5% of patients (⬆️ than standard treatments); and 15.6% saw tumors disappear completely, Jonathan Rosenberg MD reported at #ESMO22. bit.ly/3DggdLR

The TIGER trial has officially reached our target accrual! Thanks to all investigators, Alliance for Clinical Trials in Oncology, EORTC, ANZUP, Movember USA, and most of all to patients and their families. Uromigos Tom Powles silke gillessen Michael Morris, Robert Motzer MD Jonathan Rosenberg MD

Congratulations Sumanta K. Pal, MD, FASCO on being elected to the ASCO nominating committee!

Dr. Bajorin has been a transformative figure in oncology training, and I continue to learn from him every day. I am grateful to be able to have him as a colleague, mentor, and friend.

Sam Funt from ⁦Memorial Sloan Kettering Cancer Center⁩ describes an IO/IO study in refractory #germcell tumors. Minimal activity and novel mechanisms are needed. ⁦Dr. Darren Feldman⁩

ASCO #ASCO23 Great opportunity to meet colleagues I know only from Twitter & catch up with friends! ❤️Stacy Loeb, MD Cora Sternberg Shuchi Gulati MD KSridhar Shilpa Gupta Gil Morgan, MD OncoAlert Dr. Darren Feldman Sumanta K. Pal, MD, FASCO Suzanne Cole, MD Elizabeth Plimack MD KMittaloncMD Petros Grivas Toni Choueiri, MD

#ANZUP23 trials meeting off to a great start welcoming international superstars Andrea Apolo, M.D. Dr. Darren Feldman Sima Porten Alex Wyatt, Ananya Choudhury with Ben Tran Ian Davis Renu Eapen

Another exciting Plenary - Keynote Two. Chaired by 💉💉💉A/Prof. Haryana Dhillon💉💉💉 and Chun Loo Gan, this session features international speakers Andrea Apolo, M.D. Dr. Darren Feldman Alex Wyatt and Ananya Choudhury. Get ready for inspiring insights and thought-provoking discussions! #ANZUP23 #Plenary

Joining the annual meeting of Malignant Germ Cell International Consortium in Edinburgh with interesting talks on #testis #cancer therapy and miRNA in vesicles by Dr. Darren Feldman and Matthew Murray, respectively…

This article reviews contemporary evidence-based treatments for extracranial testicular germ cell tumor, the acute and chronic toxic effects that may result, and highlights recent advances and progress in the field. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… Dr. Darren Feldman Jack Gleeson

Right now, amazing clinician scientist, colleague and friend, Andrea Apollo, presenting positive results of the Alliance Ambassador Trial of adjuvant pembro vs observation following cystectomy in urothelial cancer. #GU24 Alliance for Clinical Trials in Oncology

If you take care of testicular cancer patients (or want to in the future), not going to find a more comprehensive review than this...... Dr. Darren Feldman Jack Gleeson Testicular cancer in 2023: Current status and recent progress acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

Star UrologyMSK fellow Dr. Fady Baky presenting a poster on the MSK experience with our NYS DOH approved CLIA certified serum miRNA assay in stage I testis cancer showing high accuracy for predicting viable non-teratomatous GCT. Rich Matulewicz DrBagrodia

Read our March/April issue! acsjournals.onlinelibrary.wiley.com/toc/15424863/2… In this issue: 🔹 Moffitt Cancer Center researchers on a case of dMMR/MSI-H gastric cancer 🔹 2023 ACS Research report of #CancerDisparities in the US 🔹 Testicular cancer in 2023 by Dr. Darren Feldman Jack Gleeson et al OncoAlert

Congratulations to Dr. Reuter!

My patient sent me this today! I’m so grateful. 👏🏼Cheers to our patients and our MA state legislature #testicularcancer Christopher Sweeney, MBBS Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber News Movember USA Alok Tewari Dr. Darren Feldman Toni Choueiri, MD Tim Clinton

Cabozantinib combined with nivolumab in patients with metastatic non-clear cell renal cell carcinoma ⭕️The objective response rate (ORR) was 48% ⭕️Median progression-free survival was 13 months ⭕️Median overall survival was 28 months. ⭕️Comparable results with KEYNOTE-B61,

⚡️ On European Urology - Cabozantinib + nivolumab shows promising results in non–clear cell renal cell carcinoma. With a 48% response rate and median overall survival of 28 months, this combination offers a potential new treatment option. No new safety concerns were observed.

Delighted to see this long term follow up paper for TIP combination chemotherapy for #testicularcancer / #GCT published in Journal of Clinical Oncology. Thanks to my great mentors Dr. Darren Feldman Robert Motzer MD from Memorial Sloan Kettering Cancer Center and Conquer Cancer, the ASCO Foundation for my YIA award and Cancer Research @UCC for supporting!

Great opportunity to be mentored by a tremendous team of superb clinicians in one of the strongest environments for translational an clinical research!